Boston Scientific Corporation
General ticker "BSX" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $148.3B (TTM average)
Boston Scientific Corporation follows the US Stock Market performance with the rate: 18.8%.
Estimated limits based on current volatility of 2.2%: low 88.72$, high 92.64$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 53000 as of 2024
- US accounted for 9.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Economic downturns and volatility, Supply chain disruptions, Pandemic risks, Market competition, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [76.98$, 107.05$]
- 2025-12-31 to 2026-12-31 estimated range: [81.52$, 113.24$]
Financial Metrics affecting the BSX estimates:
- Negative: with PPE of 35.8 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 15.54
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 4.48
- Positive: 0.04 < Operating cash flow per share per price, % of 2.60
- Positive: -4.41 < Investing cash flow per share per price, % of -4.31
- Positive: 42.53 < Shareholder equity ratio, % of 55.26 <= 64.17
- Positive: Industry inventory ratio change (median), % of -1.22 <= -0.18
Short-term BSX quotes
Relationship graph
Long-term BSX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $12,660.00MM | $14,240.00MM | $16,747.00MM |
| Operating Expenses | $11,011.00MM | $11,897.00MM | $14,144.00MM |
| Operating Income | $1,649.00MM | $2,343.00MM | $2,603.00MM |
| Non-Operating Income | $-508.00MM | $-358.00MM | $-321.00MM |
| Interest Expense | $470.00MM | $265.00MM | $305.00MM |
| R&D Expense | $1,323.00MM | $1,414.00MM | $1,615.00MM |
| Income(Loss) | $1,141.00MM | $1,985.00MM | $2,282.00MM |
| Taxes | $443.00MM | $393.00MM | $436.00MM |
| Profit(Loss)* | $698.00MM | $1,593.00MM | $1,854.00MM |
| Stockholders Equity | $17,574.00MM | $19,282.00MM | $21,770.00MM |
| Inventory | $1,867.00MM | $2,484.00MM | $2,810.00MM |
| Assets | $32,470.00MM | $35,136.00MM | $39,395.00MM |
| Operating Cash Flow | $1,526.00MM | $2,503.00MM | $3,435.00MM |
| Capital expenditure | $612.00MM | $800.00MM | $790.00MM |
| Investing Cash Flow | $-2,011.00MM | $-2,574.00MM | $-5,687.00MM |
| Financing Cash Flow | $-548.00MM | $5.00MM | $1,814.00MM |
| Earnings Per Share** | $0.49 | $1.10 | $1.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.